Pharmaceutical companies are chipping away at India's legal safeguards in the courts...Bayer is attempting to clamp down on and delay the approval process required for generics to be marketed as soon as a patent is licensed, revoked or expires. Novartis, having lost a legal marathon challenging the very constitutionality of the most significant parts of Indian patent law, is now before the Indian Supreme Court to water down the use of these crucial provisions. [also refers to Gilead Sciences]